NRx Pharmaceuticals (NASDAQ:NRXP) Cut to “Strong Sell” at Zacks Research

Zacks Research lowered shares of NRx Pharmaceuticals (NASDAQ:NRXP) from a hold rating to a strong sell rating in a research report sent to investors on Monday morning,Zacks.com reports.

NRXP has been the subject of several other research reports. BTIG Research reissued a “buy” rating and issued a $25.00 price target on shares of NRx Pharmaceuticals in a research note on Thursday, January 15th. Ascendiant Capital Markets reiterated a “buy” rating and issued a $48.00 target price (up from $47.00) on shares of NRx Pharmaceuticals in a report on Friday, January 2nd. HC Wainwright reissued a “buy” rating on shares of NRx Pharmaceuticals in a research report on Wednesday, January 21st. D. Boral Capital restated a “buy” rating and set a $34.00 price target on shares of NRx Pharmaceuticals in a report on Monday, January 5th. Finally, Wall Street Zen upgraded shares of NRx Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Sunday, November 23rd. Four analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $36.75.

NRx Pharmaceuticals Stock Performance

NRXP stock opened at $2.11 on Monday. The company has a market capitalization of $62.46 million, a P/E ratio of -0.90 and a beta of 1.62. The company has a fifty day moving average price of $2.31 and a 200-day moving average price of $2.67. NRx Pharmaceuticals has a 52-week low of $1.58 and a 52-week high of $3.84.

NRx Pharmaceuticals (NASDAQ:NRXP) last posted its quarterly earnings data on Friday, November 14th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.07). The company had revenue of $0.24 million during the quarter, compared to analyst estimates of $6.83 million. As a group, sell-side analysts forecast that NRx Pharmaceuticals will post -1.75 earnings per share for the current fiscal year.

Institutional Trading of NRx Pharmaceuticals

Several large investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in shares of NRx Pharmaceuticals by 27.9% during the 2nd quarter. Geode Capital Management LLC now owns 172,255 shares of the company’s stock valued at $562,000 after acquiring an additional 37,598 shares during the period. Ethos Financial Group LLC acquired a new position in shares of NRx Pharmaceuticals during the third quarter valued at about $39,000. One Wealth Management Investment & Advisory Services LLC raised its holdings in shares of NRx Pharmaceuticals by 86.1% during the third quarter. One Wealth Management Investment & Advisory Services LLC now owns 27,991 shares of the company’s stock valued at $92,000 after purchasing an additional 12,950 shares during the period. AdvisorShares Investments LLC boosted its position in shares of NRx Pharmaceuticals by 29.7% during the 3rd quarter. AdvisorShares Investments LLC now owns 342,136 shares of the company’s stock worth $1,129,000 after purchasing an additional 78,339 shares in the last quarter. Finally, Vanguard Group Inc. grew its stake in shares of NRx Pharmaceuticals by 18.3% in the 3rd quarter. Vanguard Group Inc. now owns 534,956 shares of the company’s stock valued at $1,765,000 after buying an additional 82,781 shares during the period. Institutional investors and hedge funds own 4.27% of the company’s stock.

About NRx Pharmaceuticals

NRx Pharmaceuticals, Inc is a clinical-stage specialty biopharmaceutical company focused on the development and repurposing of small-molecule therapeutics for central nervous system and rare disease indications. The company’s research strategy centers on advancing compounds with established safety profiles into new neurological and inflammatory conditions, leveraging translational science and biomarker-driven trial design to accelerate clinical development. NRx’s pipeline includes Ifenprodil, an NMDA receptor antagonist in investigation for acute respiratory distress syndrome and inflammatory muscle disorders, as well as investigational formulations targeting depressive and cognitive disorders.

Since securing global rights to its lead assets, NRx has initiated multiple proof-of-concept studies in the United States and Europe, collaborating with academic institutions and clinical research organizations to evaluate safety and efficacy across a range of indications.